Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma

Cristina Meazza, Michela Casanova, Roberto Luksch, Marta Podda, Francesca Favini, Graziella Cefalo, Maura Massimino, Andrea Ferrari

Research output: Contribution to journalArticle

Abstract

Background: Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate. Prolonged continuous infusion seems an attractive administration modality. Methods: Ifosfamide 14 g/m 2 (with mesna 14 g/m 2) was administered through an ambulatory portable pump over 14 days as a continuous infusion, starting every 3 weeks, in 14 patients with relapsing sarcomas. No growth factors were given. Results: Acute grade 3 hematological toxicity was observed in only 13/66 cycles and red cell transfusions were given in two patients. Hematuria and dysuria occurred in three cases. The response rate was: five partial responses, five stable disease. The median time to progression was 3 months (range: 2-19 months). The best response rate was seen for synovial sarcoma and Ewing sarcoma. Conclusion: Prolonged 14-day continuous infusion of high-dose ifosfamide is well tolerated. Potentially interesting preliminary responses in pediatric patients already treated with ifosfamide are reported. Pediatr Blood Cancer.

Original languageEnglish
Pages (from-to)617-620
Number of pages4
JournalPediatric Blood and Cancer
Volume55
Issue number4
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Ifosfamide
Sarcoma
Pediatrics
Mesna
Synovial Sarcoma
Dysuria
Ewing's Sarcoma
Hematuria
Intercellular Signaling Peptides and Proteins
Cell Cycle
Neoplasms

Keywords

  • Bone sarcomas
  • Chemotherapy
  • Continuous infusion
  • High-dose
  • Ifosfamide
  • Pediatric sarcomas
  • Relapsing sarcomas
  • Soft tissue sarcomas

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

@article{aaf9628ee62c49a6a1d79976003cfc3e,
title = "Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma",
abstract = "Background: Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate. Prolonged continuous infusion seems an attractive administration modality. Methods: Ifosfamide 14 g/m 2 (with mesna 14 g/m 2) was administered through an ambulatory portable pump over 14 days as a continuous infusion, starting every 3 weeks, in 14 patients with relapsing sarcomas. No growth factors were given. Results: Acute grade 3 hematological toxicity was observed in only 13/66 cycles and red cell transfusions were given in two patients. Hematuria and dysuria occurred in three cases. The response rate was: five partial responses, five stable disease. The median time to progression was 3 months (range: 2-19 months). The best response rate was seen for synovial sarcoma and Ewing sarcoma. Conclusion: Prolonged 14-day continuous infusion of high-dose ifosfamide is well tolerated. Potentially interesting preliminary responses in pediatric patients already treated with ifosfamide are reported. Pediatr Blood Cancer.",
keywords = "Bone sarcomas, Chemotherapy, Continuous infusion, High-dose, Ifosfamide, Pediatric sarcomas, Relapsing sarcomas, Soft tissue sarcomas",
author = "Cristina Meazza and Michela Casanova and Roberto Luksch and Marta Podda and Francesca Favini and Graziella Cefalo and Maura Massimino and Andrea Ferrari",
year = "2010",
month = "10",
doi = "10.1002/pbc.22596",
language = "English",
volume = "55",
pages = "617--620",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump

T2 - Feasibility and efficacy in refractory pediatric sarcoma

AU - Meazza, Cristina

AU - Casanova, Michela

AU - Luksch, Roberto

AU - Podda, Marta

AU - Favini, Francesca

AU - Cefalo, Graziella

AU - Massimino, Maura

AU - Ferrari, Andrea

PY - 2010/10

Y1 - 2010/10

N2 - Background: Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate. Prolonged continuous infusion seems an attractive administration modality. Methods: Ifosfamide 14 g/m 2 (with mesna 14 g/m 2) was administered through an ambulatory portable pump over 14 days as a continuous infusion, starting every 3 weeks, in 14 patients with relapsing sarcomas. No growth factors were given. Results: Acute grade 3 hematological toxicity was observed in only 13/66 cycles and red cell transfusions were given in two patients. Hematuria and dysuria occurred in three cases. The response rate was: five partial responses, five stable disease. The median time to progression was 3 months (range: 2-19 months). The best response rate was seen for synovial sarcoma and Ewing sarcoma. Conclusion: Prolonged 14-day continuous infusion of high-dose ifosfamide is well tolerated. Potentially interesting preliminary responses in pediatric patients already treated with ifosfamide are reported. Pediatr Blood Cancer.

AB - Background: Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate. Prolonged continuous infusion seems an attractive administration modality. Methods: Ifosfamide 14 g/m 2 (with mesna 14 g/m 2) was administered through an ambulatory portable pump over 14 days as a continuous infusion, starting every 3 weeks, in 14 patients with relapsing sarcomas. No growth factors were given. Results: Acute grade 3 hematological toxicity was observed in only 13/66 cycles and red cell transfusions were given in two patients. Hematuria and dysuria occurred in three cases. The response rate was: five partial responses, five stable disease. The median time to progression was 3 months (range: 2-19 months). The best response rate was seen for synovial sarcoma and Ewing sarcoma. Conclusion: Prolonged 14-day continuous infusion of high-dose ifosfamide is well tolerated. Potentially interesting preliminary responses in pediatric patients already treated with ifosfamide are reported. Pediatr Blood Cancer.

KW - Bone sarcomas

KW - Chemotherapy

KW - Continuous infusion

KW - High-dose

KW - Ifosfamide

KW - Pediatric sarcomas

KW - Relapsing sarcomas

KW - Soft tissue sarcomas

UR - http://www.scopus.com/inward/record.url?scp=77957090848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957090848&partnerID=8YFLogxK

U2 - 10.1002/pbc.22596

DO - 10.1002/pbc.22596

M3 - Article

C2 - 20589638

AN - SCOPUS:77957090848

VL - 55

SP - 617

EP - 620

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -